Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)

Market Cap	10.03B +0.6%
Revenue (ttm)	4.68B -18.1%
Net Income	23.88M +0.9%
EPS	0.01 +14.4%
Shares Out	3.00B
PE Ratio	268.10
Forward PE	n/a
Dividend	0.03 (0.91%)
Ex-Dividend Date	Jun 24, 2025

Volume	16,208,400
Average Volume	31,768,287
Open	3.320
Previous Close	3.340
Day's Range	3.270 - 3.330
52-Week Range	3.220 - 4.490
Beta	0.13
RSI	40.19
Earnings Date	Apr 21, 2026

About SHE:300026

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet based therapy. It is also involved in the research and development of various drugs in the areas of sepsis, pulmonary hypertension, leukemia, cardiovascular and cerebrovascular diseases, arthritis, ischemic stroke, HCV, vascular disease, psychosis, and chemother...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 4,852
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300026

Financial Performance

In 2025, SHE:300026's revenue was 4.94 billion, a decrease of -14.55% compared to the previous year's 5.78 billion. Earnings were 18.50 million, a decrease of -13.85%.